文献速递支持与姑息治疗胸部肿瘤骨软组织肉瘤与黑色素瘤

免疫检查点抑制剂再挑战在免疫相关不良事件后的安全性评估

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
PubMed 文献 · JAMA Oncol · 2019-01-01

该队列研究纳入93例在法国Gustave Roussy癌症中心因≥2级免疫相关不良事件(irAE)接受评估的成人患者,其中40例(43%)重新接受抗PD-1或抗PD-L1治疗。中位随访14个月,再挑战患者中55%出现相同或不同irAE,且第二次irAE严重程度不高于首次;较短的首发irAE出现时间与二次irAE发生相关(9 vs 15周;结论认为再挑战的风险获益比可接受,但需密切监测并需前瞻性试验进一步研究。

要点

  • 再挑战后55%患者出现二次irAE,但严重程度不高于首次。
  • 再挑战的风险获益比可接受,但需密切监测。

核心结论

  • 抗PD-1或抗PD-L1再挑战的风险获益比似乎可接受,但患者需密切监测,并需前瞻性临床试验进一步研究再挑战条件。

研究设计与样本

  • 这项队列研究纳入2015年8月1日至2017年12月31日期间转诊至法国Villejuif的Gustave Roussy癌症中心ImmunoTOX评估板的连续成人患者93例。
  • 数据分析时间为2018年5月28日至11月25日,主要终点为首次≥2级irAE后重新接受抗PD-1或抗PD-L1治疗患者中第二次irAE的发生率。

主要发现

  • 93例患者中48例(52%)为女性,中位年龄62.5岁(范围33-85岁),主要肿瘤类型为黑色素瘤31例(33%)、肺癌15例(16%)、结直肠癌8例(9%)和淋巴瘤8例(9%)。
  • 初始irAE为2级43例(46%)、3级36例(39%)、4级14例(15%),主要表现为肝炎17例(18%)、皮肤毒性14例(15%)、肺炎13例(14%)、结肠炎11例(12%)和关节痛7例(7.5%)。
  • 40例(43%)患者重新接受相同的抗PD-1或抗PD-L1药物治疗,再挑战组与非再挑战组在中位年龄、初始irAE出现时间、irAE严重程度和类固醇使用方面无显著差异。

临床怎么用

  • 对于发生≥2级irAE的癌症患者,可考虑在密切监测下重新使用抗PD-1或抗PD-L1治疗。
  • 首发irAE出现时间较短的患者再挑战后二次irAE风险较高,应加强监测。

局限性

  • 再挑战条件需通过前瞻性临床试验进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although immune checkpoint inhibitors (ICIs), such as anti-PD-1 (programmed cell death 1) or anti-PD-L1 (programmed cell death 1 ligand 1), have proved effective in treating many cancers, patients receiving ICIs may experience immune-related adverse events (irAEs). Little evidence exists on the safety of resuming these treatments after an irAE. OBJECTIVE: To investigate the safety of a rechallenge with anti-PD-1 or anti-PD-L1 immunotherapies after an irAE. DESIGN, SETTING, AND PARTICIPANTS: This cohort study of the safety of an ICI rechallenge involved consecutive adult patients (n = 93) who were referred to the ImmunoTOX assessment board at the Gustave Roussy cancer center in Villejuif, France, between August 1, 2015, and December 31, 2017. Data were analyzed from May 28 to November 25, 2018. MAIN OUTCOMES AND MEASURES: Incidence of a second irAE in patients who had a readministration of an anti-PD-1 or anti-PD-L1 inhibitor after an initial grade 2 or higher irAE. Characteristics of the patients and the irAEs were reviewed, and the primary end point was the rate of occurrence of second irAEs. RESULTS: A total of 93 patients were included, among whom 48 (52%) were female, and the median (range) age was 62.5 (33-85) years. The main cancer types or tumor sites were melanoma (31 [33%]), lung (15 [16%]), colorectal (8 [9%]), and lymphoma (8 [9%]). For the initial irAE, 43 grade 2 events (46%), 36 grade 3 events (39%), and 14 grade 4 events (15%) were found, presenting primarily as hepatitis (17 [18%]), skin toxic effect (14 [15%]), pneumonitis (13 [14%]), colitis (11 [12%]), or arthralgia (7 [7.5%]). Forty patients (43%) were rechallenged with the same anti-PD-1 or anti-PD-L1 agent. The rechallenged and non-rechallenged groups did not differ in terms of median (range) age (61 [34-84] years vs 63 [33-85] years; P = .37), time to initial irAE (5 [1-40] treatment cycles vs 3 [1-22] treatment cycles; P = .32), irAE severity (grade 2: 18 [47.5%] vs 27 [51%]; grades 3-4: 22 [52.5%] vs 26 [49%]; P = .70), or steroid use (17 [42.5%] vs 32 [60%]; P = .09). With a median follow-up period of 14 months, the same irAE or a different irAE occurred in 22 patients (55%). Shorter time to the initial irAE was linked to the occurrence of a second irAE (9 vs 15 weeks; P = .04). The second irAEs were not found to be more severe than the first. CONCLUSIONS AND RELEVANCE: The risk-reward ratio for an anti-PD-1 or anti-PD-L1 rechallenge appears to be acceptable, although these patients require close monitoring; further investigation into rechallenge conditions through a prospective clinical trial is needed.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2019. PMID: 31169866. doi:10.1001/jamaoncol.2019.1022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。